nference Establishes AI Initiative with Takeda to Advance Precision Medicine in Inflammatory Bowel DiseaseBusiness Wire • 07/17/24
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV TherapiesBusiness Wire • 06/24/24
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune ThrombocytopeniaBusiness Wire • 06/23/24
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal CancerBusiness Wire • 06/21/24
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual MeetingBusiness Wire • 06/18/24
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?Benzinga • 06/17/24
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut SyndromeBusiness Wire • 06/17/24
Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)PRNewsWire • 06/14/24
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)Business Wire • 06/14/24
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across MassachusettsBusiness Wire • 06/11/24
Celiac Disease Market and Epidemiology Analysis 2018-2034 with Detailed Profiles of Marketed and Pipeline Drugs, Including KAN-101 (Kanyos Bio) and TIMP-GLIA/TAK 101 (Takeda)GlobeNewsWire • 06/07/24
Takeda's TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to PlaceboBusiness Wire • 06/03/24
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin LymphomaBusiness Wire • 06/01/24
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)Business Wire • 05/31/24
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual MeetingBusiness Wire • 05/14/24
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's DiseaseBusiness Wire • 05/13/24
Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call TranscriptSeeking Alpha • 05/10/24
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin ExpansionBusiness Wire • 05/09/24